Puretech Health Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Puretech Health Plc (PRTC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Puretech Health Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 5M vs 102,464M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+18.5%) for its tracked peer group.
- Growth: Puretech Health Plc generated -3.5% revenue growth year over year in Q4 2025, vs 12.5% for its tracked competitors combined.
- Profitability: Its -2,362.8% net margin compares with 12.8% for the peer group.
- Peer revenue share: Puretech Health Plc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.04M compares with $1.13M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PRTC Sales vs. its Competitors, Q4 2025
Puretech Health Plc reported revenue contraction of 3.50 % year on year in Q4 2025, below its competitors' combined revenue growth of 12.50 %.
With a net margin of -2,362.82 %, Puretech Health Plc reported lower profitability than its competitors (12.75 %).
Puretech Health Plc generated 0.02 % of the combined sales of its peer group, up from 0.02 % a year earlier.
Puretech Health Plc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Puretech Health Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Puretech Health Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Puretech Health Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -3.5% for Puretech Health Plc. Puretech Health Plc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Puretech Health Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Puretech Health Plc | - | No | No | No |
| Competitors combined (39) | ||||
| High-Confidence Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PRTC Stock Performance relative to its Competitors
PRTC Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Verona Pharma Plc | 282.9% | Outperformed |
| 2 | Day One Biopharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Shattuck Labs Inc | 282.9% | Outperformed |
| 4 | Precigen Inc | 282.9% | Outperformed |
| 5 | Teva Pharmaceutical Industries Limited | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Puretech Health Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Puretech Health Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Puretech Health Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Puretech Health Plc | - | 4.66 |
| Amgen Inc | 230,460.16 | 38,095.00 |
| Vertex Pharmaceuticals Inc | 134,421.50 | 12,587.20 |
| Argenx Se | 64,091.92 | 8,399.37 |
| Teva Pharmaceutical Industries Limited | 46,378.65 | 14,105.00 |
| Alnylam Pharmaceuticals Inc | 35,133.05 | 4,804.18 |
| SUBTOTAL | 596,068.70 | 103,439.62 |
Sign in to see all competitors of Puretech Health Plc.
Sources: Puretech Health Plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Puretech Health Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Puretech Health Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Celltaxis | Named by the company | 85% |
| Jazz Pharmaceuticals | Named by the company | 85% |
| Sage Therapeutics | Named by the company | 85% |
| Senstar Technologies Corporation | Named by the company | 85% |
| Boehringer Ingelheim | Named by the company | 85% |
| Genentech | Named by the company | 85% |
| Merck | Named by the company | 85% |
| Zynerba Pharmaceuticals | Named by the company | 85% |
| Amgen | Named by the company | 85% |
| Emerald Health Pharmaceuticals | Named by the company | 85% |
| JnJ | Named by the company | 85% |
| Theralymph | Named by the company | 85% |
| Cardiol Therapeutics | Named by the company | 85% |
| Herantis Pharma | Named by the company | 85% |
| PHARMENTERPRISES | Named by the company | 85% |
| Portage Biotech Inc | Named by the company | 85% |
| BMS | Named by the company | 85% |
| Fibrogen | Named by the company | 85% |
| Marinus Pharmaceuticals | Named by the company | 85% |
| United Therapeutics | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Puretech Health Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Puretech Health Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
| Viatris Inc | Developed Markets 57.61 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Puretech Health Plc.
Puretech Health Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Puretech Health Plc | - | 39,483 | -932,915 |
| Amgen Inc | 230,460 | 2,930,385 | 672,538 |
| Vertex Pharmaceuticals Inc | 134,421 | 31,079,506 | 10,877,037 |
| Argenx Se | 64,092 | 7,316,521 | 1,125,466 |
| Teva Pharmaceutical Industries Limited | 46,379 | 415,464 | 20,884 |
| Alnylam Pharmaceuticals Inc | 35,133 | 1,921,673 | 323,195 |
| PEERS TOTAL | 596,069 | 1,129,301 | 153,116 |
Sign in to see all peers for Puretech Health Plc.
Puretech Health Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Jazz Pharmaceuticals Plc | United States 89.79 % |
| Therapeuticsmd Inc | Non Us 66.30 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Puretech Health Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Puretech Health Plc's industry classification, broader than the peer set above. Market cap in millions of $.Puretech Health Plc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 824, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,054,271 | 19.27 % |
| 2 | Johnson and Johnson | 662,243 | 12.10 % |
| 3 | Beone Medicines Ltd | 543,752 | 9.94 % |
| 4 | Abbvie Inc | 473,291 | 8.65 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Puretech Health Plc | 476 | 0.00 % |
Market cap and industry share for the rest of Puretech Health Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-07-17.
Puretech Health Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 64.89 % (avg) | -64.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -7.21 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.13 % | 4.92 % (avg) | -4.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Puretech Health Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -78.68 % | 44.98 % | -3.50 % |
| Operating Margin | - | - | - |
| Return on Invested Capital | -13.06 % | -13.83 % | -12.24 % |
| P/E | - | 10.0x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Puretech Health Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 824 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.13 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Puretech Health Plc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Puretech Health Plc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Puretech Health Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Return on equity 62.3 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (48.60 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Puretech Health Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Puretech Health Plc | 5.45 | 6.59 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Argenx Se | 2.64 | 5.23 | - |
| Teva Pharmaceutical Industries Limited | 0.24 | 1.00 | 2.15 |
| Alnylam Pharmaceuticals Inc | 1.12 | 2.86 | 1.18 |
Sign in to see all peers for Puretech Health Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Puretech Health Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Puretech Health Plc | Q4 2025 | -3.5 % | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Argenx Se | Q4 2025 | +89.1 % | +55.1 % |
| Teva Pharmaceutical Industries Limited | Q2 2026 | -0.8 % | - |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +66.9 % | - |
| PEERS TOTAL | +22.9 % | +45.5 % |
Sign in to see all peers for Puretech Health Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Puretech Health Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Puretech Health Plc | Q4 2025 | - | -45.5 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Argenx Se | Q4 2025 | +44.6 % | +242.3 % |
| Teva Pharmaceutical Industries Limited | Q2 2026 | -4.1 % | - |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +110.0 % | +142.6 % |
Sign in to see all peers for Puretech Health Plc.
Puretech Health Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Puretech Health Plc | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Argenx Se | 14.88% | 14.81% | 17.64% |
| Teva Pharmaceutical Industries Limited | 1.77% | 2.66% | 9.11% |
| Alnylam Pharmaceuticals Inc | 15.76% | 22.10% | 93.61% |
Sign in to see all peers for Puretech Health Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Puretech Health Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Puretech Health Plc | - | - |
| Amgen Inc | 26.31 | 6.05 |
| Vertex Pharmaceuticals Inc | 30.71 | 10.68 |
| Argenx Se | 49.60 | 7.63 |
| Teva Pharmaceutical Industries Limited | 65.41 | 3.29 |
| Alnylam Pharmaceuticals Inc | 44.97 | 7.31 |
| PEERS AVERAGE | 42.84 | 5.76 |
Sign in to see all peers for Puretech Health Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.